 WTHI |
Amylin Seeks FDA Approval on Extended Byetta Treatment
Wall Street Journal By DAVID BENOIT NEW YORK — Amylin Pharmaceuticals Inc. has submitted a new drug application to the Food and Drug Administration for the once-a-week version of its diabetes treatment Byetta, a potential blockbuster drug for the biopharmaceutical … Calif. Drug Maker Seeks Approval for Once-a-Week Diabetes Treatment Attorney at Law Exenatide Once Weekly New Drug Application Submitted to FDA for … PR Newswire (press release) Amylin Shares Jump on NDA but Drug Class Concerns Linger BioWorld Online Trading Markets (press release) – MarketWatch all 205 news articles |
More details can be found at www.diabeteshowto.com
Discussion
Comments are disallowed for this post.
Comments are closed.